| Literature DB >> 30242261 |
Alejandro Cabezas-Cruz1, Pedro J Espinosa2, Pilar Alberdi2, Ladislav Šimo3, James J Valdés4,5,6, Lourdes Mateos-Hernández3,2, Marinela Contreras2, Margarita Villar Rayo2, José de la Fuente7,8.
Abstract
The carbohydrate Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal) is produced in all mammals except for humans, apes and old world monkeys that lost the ability to synthetize this carbohydrate. Therefore, humans can produce high antibody titers against α-Gal. Anti-α-Gal IgE antibodies have been associated with tick-induced allergy (i.e. α-Gal syndrome) and anti-α-Gal IgG/IgM antibodies may be involved in protection against malaria, leishmaniasis and Chagas disease. The α-Gal on tick salivary proteins plays an important role in the etiology of the α-Gal syndrome. However, whether ticks are able to produce endogenous α-Gal remains currently unknown. In this study, the Ixodes scapularis genome was searched for galactosyltransferases and three genes were identified as potentially involved in the synthesis of α-Gal. Heterologous gene expression in α-Gal-negative cells and gene knockdown in ticks confirmed that these genes were involved in α-Gal synthesis and are essential for tick feeding. Furthermore, these genes were shown to play an important role in tick-pathogen interactions. Results suggested that tick cells increased α-Gal levels in response to Anaplasma phagocytophilum infection to control bacterial infection. These results provided the molecular basis of endogenous α-Gal production in ticks and suggested that tick galactosyltransferases are involved in vector development, tick-pathogen interactions and possibly the etiology of α-Gal syndrome in humans.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30242261 PMCID: PMC6154994 DOI: 10.1038/s41598-018-32664-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Galactosyltransferase genes in the I. scapularis genome.
| Enzyme | Gene names | Genome accession | Exons* | Length (aa) | Predicted Location** |
|---|---|---|---|---|---|
|
| |||||
| β1,4-galactosyltransferases | |||||
| β1,4-galactosyltransferase 1 |
| ISCW000936 | 5 | 246† | Cytoplasm |
| β1,4-galactosyltransferase 1 |
| ISCW004931 | 1 | 296 | Cytoplasm |
| β1,4-galactosyltransferase 1 |
| ISCW004365 | 1 | 356 | Golgi |
| β1,4-galactosyltransferase 1 |
| ISCW001614 | 3 | 248 | Golgi |
| β1,4-galactosyltransferase 1 |
| ISCW007584 | 3 | 210 | Golgi |
| β1,4-galactosyltransferase 1 |
| ISCW008096 | 1 | 69† | Extracellular |
| β1,4-galactosyltransferase 2 |
| ISCW001068 | 2 | 65† | Mitochondrion |
| β1,4-galactosyltransferase 3 |
| ISCW017744 | 6 | 257 | Cytoplasm |
| β1,4-galactosyltransferase 4 |
| ISCW017743 | 1 | 110 | Extracellular |
| β1,4-galactosyltransferase 7 |
| ISCW003979 | 1 | 290 | Extracellular |
|
| |||||
| β1,3-galactosyltransferases | |||||
| β1,3-galactosyltransferase 1 |
| ISCW010849 | 2 | 357 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW015763 | 1 | 351 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW011417 | 2 | 352 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW018107 | 2 | 322† | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW003896 | 1 | 333 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW017668 | 1 | 387 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW003730 | 1 | 316 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW002872 | 1 | 351 | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW024867 | 1 | 248† | Cytoplasm |
| β1,3-galactosyltransferase 1 |
| ISCW024567 | 1 | 306† | Golgi |
| β1,3-galactosyltransferase 1 |
| ISCW007189 | 1 | 328† | Golgi |
| β1,3-galactosyltransferase 2 |
| ISCW011351 | 2 | 284† | Golgi |
| β1,3-galactosyltransferase 2-like |
| ISCW024612 | 1 | 181† | Mitochondrion |
| β1,3-galactosyltransferase 2-like |
| ISCW024301 | 1 | 178† | Cytoplasm |
| β1,3-galactosyltransferase 4 |
| ISCW012063 | 1 | 127† | Extracellular |
| β1,3-galactosyltransferase 4 |
| ISCW001135 | 3 | 182 | Mitochondrion |
| β1,3-galactosyltransferase 5 |
| ISCW011715 | 1 | 360 | Golgi |
| β1,3-galactosyltransferase 5 |
| ISCW007645 | 2 | 93† | Mitochondrion |
| β1,3-galactosyltransferase 5 |
| ISCW016209 | 3 | 335 | Cytoplasm |
| β1,3-galactosyltransferase 5 |
| ISCW023135 | 1 | 318 | Golgi |
| β1,3-galactosyltransferase 5 |
| ISCW011481 | 1 | 319† | Golgi |
| β1,3-galactosyltransferase 5 |
| ISCW000284 | 1 | 377 | Golgi |
| β1,3-galactosyltransferase 5 |
| ISCW000285 | 1 | 219† | Cytoplasm |
| β1,3-galactosyltransferase 5 |
| ISCW012253 | 2 | 214 | Cytoplasm |
| β1,3-galactosyltransferase 5 |
| ISCW017560 | 1 | 216† | Cytoplasm |
| β1,3-galactosyltransferase 5 |
| ISCW022168 | 1 | 303 | Mitochondrion |
| β1,3-galactosyltransferase 5 |
| ISCW001134 | 2 | 232 | Endoplasmic reticulum |
| β1,3-galactosyltransferase 5 |
| ISCW013698 | 1 | 344 | Extracellular |
| β1,3-galactosyltransferase 6 |
| ISCW012863 | 1 | 319 | Endoplasmic reticulum |
| β1,3-galactosyltransferase 7 |
| ISCW016807 | 3 | 301† | Cytoplasm |
| β1,3-galactosyltransferase 7 |
| ISCW007452 | 7 | 322 | Cytoplasm |
| β1,3-galactosyltransferase 7 |
| ISCW015124 | 6 | 396 | Cytoplasm |
| β1,3-galactosyltransferase 1/brainiac |
| ISCW013734 | 1 | 339 | Golgi |
| β1,3-galactosyltransferase 1/brainiac |
| ISCW005339 | 1 | 404 | Golgi |
| β1,3-galactosyltransferase 5/brainiac |
| ISCW010896 | 1 | 325 | Endoplasmic reticulum |
| β1,3-galactosyltransferase 5/brainiac |
| ISCW014984 | 2 | 276 | Golgi |
| β1,3-galactosyltransferase 5/brainiac |
| ISCW014983 | 2 | 429 | Golgi |
| β1,3-galactosyltransferase 5/brainiac |
| ISCW007178 | 1 | 348† | Golgi |
| β1,3-galactosyltransferase 5/brainiac |
| ISCW007342 | 1 | 337 | Golgi |
|
| |||||
| α1,4-galactosyltransferases*** | |||||
| α1,4-galactosyltransferases-1 |
| ISCW024908 | 1 | 300† | Mitochondrion |
| α1,4-galactosyltransferases-2 |
| ISCW006262 | 2 | 344 | Golgi |
| α1,4-galactosyltransferases-3 |
| ISCW023632 | 1 | 299† | Mitochondrion |
| α1,4-galactosyltransferases-4 |
| ISCW016806 | 1 | 186 | Mitochondrion |
| α1,4-galactosyltransferases-5 |
| ISCW001764 | 1 | 276 | Mitochondrion |
| α1,4-galactosyltransferases-6 |
| ISCW006436 | 3 | 293† | Mitochondrion |
| α1,4-galactosyltransferases-7 |
| ISCW013582 | 1 | 61† | Cytoplasm |
| α1,4-galactosyltransferases-8 |
| ISCW017162 | 1 | 54† | Mitochondrion |
*Data collected from VectorBase (www.vectorbase.org).
**Predicted using DeepLoc server (www.cbs.dtu.dk/services/DeepLoc/).
***Also known as Lactosylceramide 4-α-galactosyltransferases and Gb3 synthase.
†Available sequences do not include ‘START codon’ and/or ‘STOP codon’.
Figure 1Phylogenetic tree of mammalian and tick GALTs. The figure displays the phylogenetic relation between mammals (open circles) and I. scapularis (closed circles) GALTs. The four GALT families found in mammals were included in the analysis α1-3 GALTs (α3, gray), α1-4 GALTs (α4, red), β1-3 GALTs (β3, blue) and β1-4 GALTs (β4, green). Dashed lines represent that no tick ortholog was found for these proteins. Homo sapiens protein sequences were used, except for the α3 GGTA1 and iGb3 synthase (iGb3S) where Mus musculus sequences were used. Mammalian GALT protein sequences were previously reported[1]. Protein accession numbers are shown. Clusters of closely related tick GALTs were collapsed (i.e. B3GALT1, B3GALT5, A4GALT, B4GALT1 and B3GALT/brn). Only bootstraps values higher than 70% are shown. A full version of this tree is available as Supplementary Fig. S1.
Figure 2Structural characterization of tick B4GALT7 and A4GALTs. (A) The structural representation of B4GALT7 for Homo sapiens (green), Drosophila melanogaster (red) and I. scapularis (cyan) are shown with their N- and C-terminus labelled. The coloured arrows represent the respective presence of an alpha-helix in one species compared to the absence in the other two. The inset is a zoomed in representation of the active site depicting interacting residues that are color-coded to their respective structure/species. The critical residues that interact with UDP (grey sphere) and the manganese ion (Mn2+; peach sphere) are encircled. (B) The alignments show the conserved (*) and similar (.) residues for B4GALT7s and (C) A4GALTs. The metal (Mn2+) binding and the catalytic domains are shaded grey. The three B4GALT7 residues subject to mutations (Ala186Asp, Leu206Pro, and Arg270Cys) in Ehlers-Danlos syndrome, a defective connective tissue in humans, are indicated (bold ‘x’).
Figure 3Heterologous expression of tick GALTs in α-Gal-negative cells is associated to α-Gal synthesis. (A) Normalized mRNA expression of b4galt7, a4galt-1 and a4galt-2 measured by qPCR using total RNA extracted from E. coli BL21 and (B) human HL-60 cells. Gene transcription was observed in cells transformed with plasmids containing b4galt7, a4galt-1 and a4galt-2, whereas it was absent in cells transformed with the empty plasmid (Control). (C) α-Gal production was measured by flow cytometry in E. coli BL21 and (D) HL-60 cells and mean fluorescence intensity values are shown. α-Gal production was significantly higher in cells transformed with b4galt7, a4galt-1 and a4galt-2 compared with the negative control. Results were compared by Student’s t-test with unequal variance. Results are representative of three biological replicates.
Figure 4Heterologous expression of tick GALTs in HL-60 and E. coli cells is associated to α-Gal synthesis. (A) HL-60 cells were transfected with b4galt7, a4galt-1 and a4galt-2 in a fusion protein expression system that uses Red Fluorescent Protein (RFP) as a reporter of heterologous gene expression. α-Gal production was then measured by immunofluorescence. Empty plasmid was used as control. Host cell nucleus was stained with DAPI (blue). The α-Gal-specific monoclonal antibody M86 (primary antibody) and the goat anti-mouse IgM-FITC antibody (secondary antibody) were used to detect the production of α-Gal (green). RFP was also detected in human cells (red). Merged images show that the presence of α-Gal was observed exclusively in cells with heterologous gene expression (arrows). Images are at magnification X 63. (B) E. coli BL21 cells were transformed with plasmids containing b4galt7, a4galt-1 and a4galt-2. α-Gal production was then measured by immunofluorescence. Empty plasmid was used as control. Host cell nucleus was stained with DAPI (blue). The α-Gal-specific monoclonal antibody M86 (primary antibody) and the goat anti-mouse IgM-FITC antibody (secondary antibody) were used to detect the production of α-Gal (green). Merged images show the presence of α-Gal in E. coli BL21 (arrows). Images are at magnification higher than X 63. Bars represent 10 µm.
Figure 5Expression of tick galts and α-Gal levels in tissues of unfed and fed I. scapularis ticks. (A) The figure displays the mRNA expression levels of b4galt7, a4galt-1 and a4galt-2 in salivary glands (SG), midguts (MG) and ovaries (OV) of unfed and (B) fed adult I. scapularis females. mRNA levels in MG and OV are relative to the expression level in SG. (C) mRNA expression levels of b4galt7, a4galt-1 and a4galt-2 in SG, MG and OV of fed adult I. scapularis females relative to unfed ticks. (D) α-Gal levels in SG, MG and OV of unfed and fed adult I. scapularis females. Results were compared by Student’s t-test with unequal variance. Results are representative of two biological replicates.
Figure 6Tick galt genes knockdown by RNAi decreases α-Gal levels in tick tissues. (A) Unfed adult female ticks were injected with galt-specific dsRNAs or the unrelated Rs86 dsRNA control. 24 h after dsRNA injection, ticks were allowed to feed on rabbit. After engorgement, tick tissues were dissected, the levels of gene-specific mRNA were measured by qPCR and the percentage of mRNA reduction in SG, (B) MG and (C) OV were calculated. The levels of α-Gal were measured by ELISA and OD (450 nm) values for (D) SG, (E) MG and (F) OV of dsRNA-treated ticks are shown. Results were compared by Student’s t-test with unequal variance. Results are representative of two biological replicates.
Figure 7Tick galt genes knockdown by RNAi induces high mortality in ticks. Unfed adult female ticks were injected with gene-specific dsRNAs, the unrelated Rs86 dsRNA control or were non-injected. (A) 24 h after dsRNA injection, ticks were allowed to feed on rabbit. Female ticks were allowed to feed until full engorgement and tick weight and mortality were determined in individual female ticks collected after feeding. Within the first 2–3 days of feeding, 80% mortality was observed in ticks treated with dsRNA targeting the three genes (b4galt7, a4galt-1 and a4galt-2) simultaneously. (B) Tick weight was compared between ticks injected with test genes dsRNA and Rs86 control dsRNA by Student’s t-test with unequal variance. Abnormal development of the cuticle was observed in a4galt-1 dsRNA-treated ticks (blue arrows and Supplementary Fig. S6). Results are representative of two biological replicates.
Figure 8GALTs gene expression, α-Gal production and bacterial levels in A. phagocytophilum-infected IRE and HL-60 cells. (A) IRE tick cells were inoculated with A. phagocytophilum and sampled at 24 hpi and 72 hpi post-infection. The mRNA levels of b4galt7, a4galt-1 and a4galt-2 in A. phagocytophilum-infected and uninfected IRE cells were measured by qPCR normalizing against tick rsp4. (B) α-Gal production was measured by flow cytometry in A. phagocytophilum-infected and uninfected IRE cells. (C) IRE cells were treated with a pool of siRNA specific to b4galt7, a4galt-1 and a4galt-2 (b/a-4galts) or a siRNA targeting the unrelated gene Rs86 (Control). The cells were then infected with A. phagocytophilum and α-Gal production was measured by flow cytometry in A. phagocytophilum-infected and uninfected IRE cells. (D) A. phagocytophilum DNA levels were determined in A. phagocytophilum-infected and siRNA-treated (b/a-4galts) IRE cells 24 hpi and 72 hpi post-infection. Bacterial DNA levels were determined by msp4 qPCR normalizing against tick rsp4. (E) HL-60 cells were transfected with b4galt7, a4galt-1 and a4galt-2 and then infected with A. phagocytophilum. Bacterial DNA levels were measured by msp4 qPCR normalizing against human actin. Results were compared by Student’s t-test with unequal variance. Results are representative of two biological replicates.